Urology · La Mesa, CA
NPI
1588632715
Since 2006
Specialty
Urology
Code 208800000X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
8851 Center Dr, Suite 501
La Mesa, CA, 91942
Phone (619) 697-2456
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.5M
23,144 services
Medicare patients, 2024
449
Average age 77
Drug cost, 2024
$7.9M
2,042 prescriptions
Company payments, 2025
$143K
From 26 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Paul E Dato was code J0897 (injection, denosumab, 1 mg), 12,303 times for 46 patients. In total Paul E Dato billed 23,144 services in 52 codes, and Medicare paid $1.5M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-03-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 12,303 | 46 | $20.51 | $252K |
| 99489 Chronic, Principal, and Transitional Care Management | Office | 1,111 | 113 | $66.34 | $74K |
| J1952 Leuprolide injectable, camcevi, 1 mg | Office | 966 | 15 | $45.41 | $44K |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 694 | 142 | $42.94 | $30K |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 541 | 67 | $140.59 | $76K |
| 99214 Office E&M - Established | Office | 539 | 229 | $105.25 | $57K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 489 | 246 | $14.39 | $7,037 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 380 | 143 | $55.45 | $21K |
| 99487 Chronic, Principal, and Transitional Care Management | Office | 272 | 114 | $120.16 | $33K |
| 96402 Chemotherapy Administration | Office | 268 | 89 | $32.18 | $8,625 |
| 99442 Telephone Services | Office | 255 | 159 | $76.37 | $19K |
| 96372 Injection Administration | Office | 200 | 108 | $12.77 | $2,553 |
| 99427 Chronic, Principal, and Transitional Care Management | Office | 176 | 72 | $37.62 | $6,620 |
| 99443 Telephone Services | Office | 154 | 92 | $107.87 | $17K |
| 99213 Office E&M - Established | Office | 128 | 94 | $67.52 | $8,642 |
By year: 2022 $1.2M for 34,817 services; 2023 $2.0M for 28,612 services; 2024 $1.5M for 23,144 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81002 Clinical Chemistry | 99 | 91 | $3.41 | $338 |
| 36415 Venipuncture Blood Collection | 39 | 30 | $8.42 | $328 |
| 81003 Clinical Chemistry | 26 | 26 | $2.20 | $57.2 |
Medicare prescription drug claims, 2024
In 2024, the drug Paul E Dato prescribed most often to Medicare patients was Orgovyx (Relugolix), with 444 prescriptions and refills. In total Paul E Dato wrote 2,042 Medicare prescriptions that cost $7.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Orgovyx Relugolix | 444 | 444 | 66 | $1.1M |
| Xtandi Enzalutamide | 242 | 242 | 40 | $3.0M |
| Prednisone Generic | 203 | 243 | 31 | $1,025 |
| Abiraterone Acetate Generic | 195 | 195 | 28 | $328K |
| Erleada Apalutamide | 130 | 143 | 21 | $1.9M |
| Tamsulosin Hcl Generic | 112 | 292 | 41 | $2,076 |
| Nubeqa Darolutamide | 80 | 80 | 12 | $1.0M |
| Ciprofloxacin Hcl Generic | 74 | 74 | 65 | $193 |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 34 | 34 | 34 | $176 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 32 | 32 | 11 | $704 |
| Myrbetriq Mirabegron | 28 | 46 | Under 11 | $20K |
| Eligard Leuprolide Acetate | 26 | 49 | Under 11 | $24K |
| Yonsa Abiraterone Acet,submicronized | 23 | 29 | Under 11 | $291K |
| Alendronate Sodium Generic | 23 | 56 | Under 11 | $123 |
| Oxycodone Hcl Generic | 18 | 18 | Under 11 | $238 |
Brand drugs: 1,027 claims; generic drugs: 1,015 claims; opioid claims: 94.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Paul E Dato $143K ($143K in general payments such as food, travel and fees) from 26 companies. The largest payer was Sun Pharmaceutical Industries Inc. with $32K.
| Company | Payments | Amount |
|---|---|---|
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 33 | $32K |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 40 | $32K |
| Janssen Biotech, Inc. JNJ | 36 | $25K |
| Dendreon Pharmaceuticals LLC | 40 | $21K |
| Edap Technomed Inc | 2 | $11K |
| Astellas Pharma US Inc 4503.T | 9 | $9,068 |
| Novartis Pharmaceuticals Corporation NVS | 6 | $4,170 |
| Telix Pharmaceuticals TLX | 6 | $3,962 |
| Ferring Pharmaceuticals Inc. | 8 | $2,761 |
| Pfizer Inc. PFE | 10 | $1,570 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.